Ultragenyx Pharmaceutical Inc.
RARE Healthcare Biotechnology
Ultragenyx Pharmaceutical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $673.0 million, up 20.2% from fiscal 2024. In the quarter to June 2026, revenue grew 28.1%, EPS grew 23.1% and free cash flow grew 12.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
Follow RARE
Ultragenyx Pharmaceutical Inc. (RARE) EV/Sales
As of 16 October 2026, Ultragenyx Pharmaceutical Inc. (RARE) trades at a EV/Sales of 1.7×. Over the past ten years it has ranged from 0.0× (September 2017) to 6,233× (October 2017); the current reading is higher than 24% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.4× | (58.68%) |
| FY2024 | 5.7× | (16.38%) |
| FY2023 | 6.8× | 1.89% |
| FY2022 | 6.7× | (52.53%) |
| FY2021 | 14.1× | (47.02%) |
| FY2020 | 26.6× | 66.35% |
| FY2019 | 16.0× | (51.61%) |
| FY2018 | 33.1× | (95.14%) |
| FY2017 | 681× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 4.3× | 71.52% |
| Mar 2026 | 2.5× | 7.20% |
| Dec 2025 | 2.4× | (42.24%) |
| Sep 2025 | 4.1× | (19.44%) |
| 35 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| RAPP Rapport Therapeutics, Inc. compare | n/m |
| MAZE Maze Therapeutics, Inc. compare | n/m |
| GPCR Structure Therapeutics Inc. Sponsored ADR compare | n/m |
| RARE Ultragenyx Pharmaceutical Inc. | 1.7× |
| IMCR Immunocore Holdings PLC Sponsored ADR compare | 2.5× |
| ANAB AnaptysBio, Inc. compare | 4.5× |
| KRSA Korsana Biosciences, Inc. compare | 8.8× |
| QURE uniQure N.V. compare | 36.8× |
| ABSI Absci Corporation compare | 704× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)